Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017 (2017), Article ID 3818292, 13 pages
https://doi.org/10.1155/2017/3818292
Research Article

The Role of Serum Adiponectin for Outcome Prediction in Patients with Dilated Cardiomyopathy and Advanced Heart Failure

1Department of Pathology, Forensic Medicine and Pharmacology, Faculty of Medicine, Vilnius University, M. K. Ciurlionio 21, LT-03101 Vilnius, Lithuania
2Department of Regenerative Medicine, State Research Institute, Center for Innovative Medicine, Santariskiu 5, LT-08406 Vilnius, Lithuania
3Department of Cardiology and Angiology, Vilnius University Hospital Santaros Klinikos, Santariskiu 2, LT-08661 Vilnius, Lithuania
4Department of Integrative Pathophysiology, Medical Faculty Mannheim, Mannheim, Germany
5Department of Physiology, Biochemistry, Microbiology and Laboratory Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania

Correspondence should be addressed to Vaida Baltrūnienė; moc.liamg@eneinurtlab.adiav

Received 28 July 2017; Revised 25 October 2017; Accepted 29 October 2017; Published 26 November 2017

Academic Editor: Stefano Cagnin

Copyright © 2017 Vaida Baltrūnienė et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Warriner, P. Sheridan, and P. Lawford, “Heart failure: Not a single organ disease but a multisystem syndrome,” British Journal of Hospital Medicine, vol. 76, no. 6, pp. 330–336, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. C. Skurk, F. Wittchen, L. Suckau et al., “Description of a local cardiac adiponectin system and its deregulation in dilated cardiomyopathy,” European Heart Journal, vol. 29, no. 9, pp. 1168–1180, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Tao, E. Gao, X. Jiao et al., “Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress,” Circulation, vol. 115, no. 11, pp. 1408–1416, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Kadowaki and T. Yamauchi, “Adiponectin and adiponectin receptors,” Endocrine Reviews, vol. 26, no. 3, pp. 439–451, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Kumada, S. Kihara, S. Sumitsuji et al., “Association of hypoadiponectinemia with coronary artery disease in men,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 1, pp. 85–89, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. Nakamura, K. Shimada, D. Fukuda et al., “Implications of plasma concentrations of adiponectin in patients with coronary artery disease,” Heart, vol. 90, no. 5, pp. 528–533, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. D. M. Maahs, L. G. Ogden, G. L. Kinney et al., “Low plasma adiponectin levels predict progression of coronary artery calcification,” Circulation, vol. 111, no. 6, pp. 747–753, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. W. J. Y. Chen, L. J. Rijzewijk, R. W. van der Meer et al., “Association of plasma osteoprotegerin and adiponectin with arterial function, cardiac function and metabolism in asymptomatic type 2 diabetic men,” Cardiovascular Diabetology, vol. 10, article 67, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Hotta, T. Funahashi, Y. Arita et al., “Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 6, pp. 1595–1599, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. Y. Iwashima, T. Katsuya, K. Ishikawa et al., “Hypoadiponectinemia is an independent risk factor for hypertension,” Hypertension, vol. 43, no. 6, pp. 1318–1323, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. S. J. Hong, C. G. Park, H. S. Seo, D. J. Oh, and Y. M. Ro, “Associations among plasma adiponectin, hypertension, left ventricular diastolic function and left ventricular mass index,” Blood Pressure, vol. 13, no. 4, pp. 236–242, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Mitsuhashi, H. Yatsuya, K. Tamakoshi et al., “Adiponectin level and left ventricular hypertrophy in Japanese men,” Hypertension, vol. 49, no. 6, pp. 1448–1454, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. S. R. Wilson, M. S. Sabatine, S. D. Wiviott et al., “Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: Observations from the Pravastatin or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22),” American Heart Journal, vol. 161, no. 6, pp. 1147–e1, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Lindberg, S. H. Pedersen, R. Møgelvang et al., “Usefulness of adiponectin as a predictor of all cause mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention,” American Journal of Cardiology, vol. 109, no. 4, pp. 492–496, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Bobbert, C. Scheibenbogen, A. Jenke et al., “Adiponectin expression in patients with inflammatory cardiomyopathy indicates favourable outcome and inflammation control,” European Heart Journal, vol. 32, no. 9, pp. 1134–1147, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. F. Maresca, V. Di Palma, M. Bevilacqua et al., “Adipokines, vascular wall, and cardiovascular disease: a focused overview of the role of adipokines in the pathophysiology of cardiovascular disease,” Angiology, vol. 66, no. 1, pp. 8–24, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. A. J. Walkey, T. W. Rice, J. Konter et al., “Plasma adiponectin and mortality in critically ill subjects with acute respiratory failure,” Critical Care Medicine, vol. 38, no. 12, pp. 2329–2334, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Kistorp, J. Faber, S. Galatius et al., “Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure,” Circulation, vol. 112, no. 12, pp. 1756–1762, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Nakamura, H. Funayama, N. Kubo et al., “Association of hyperadiponectinemia with severity of ventricular dysfunction in congestive heart failure,” Circulation Journal, vol. 70, no. 12, pp. 1557–1562, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. Arita, S. Kihara, N. Ouchi et al., “Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity,” Biochemical and Biophysical Research Communications, vol. 257, no. 1, pp. 79–83, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. A. L. Beatty, M. H. Zhang, I. A. Ku, B. Na, N. B. Schiller, and M. A. Whooley, “Adiponectin is associated with increased mortality and heart failure in patients with stable ischemic heart disease: Data from the Heart and Soul Study,” Atherosclerosis, vol. 220, no. 2, pp. 587–592, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Kung, T. Szabó, J. Springer, W. Doehner, S. D. Anker, and S. von Haehling, “Cachexia in heart disease: Highlights from the ESC 2010,” Journal of Cachexia, Sarcopenia and Muscle, vol. 2, no. 1, pp. 63–69, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. J. George, S. Patal, D. Wexler et al., “Circulating adiponectin concentrations in patients with congestive heart failure,” Heart, vol. 92, no. 10, pp. 1420–1424, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Celik and H. Yaman, “Elevated adiponectin levels in patients with chronic heart failure: An independent predictor of mortality or a marker of cardiac cachexia?” International Journal of Cardiology, vol. 144, no. 2, pp. 319-320, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Tamura, Y. Furukawa, R. Taniguchi et al., “Serum adiponectin level as an independent predictor of mortality in patients with congestive heart failure,” Circulation Journal, vol. 71, no. 5, pp. 623–630, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Sente, A. Gevaert, A. Van Berendoncks, C. J. Vrints, and V. Y. Hoymans, “The evolving role of adiponectin as an additive biomarker in HFrEF,” Heart Failure Reviews, vol. 21, no. 6, pp. 753–769, 2016. View at Publisher · View at Google Scholar · View at Scopus
  27. J. J. V. McMurray, S. Adamopoulos, S. D. Anker et al., “ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the european society of cardiology. Developed in collaboration with the heart Failure Association (HFA) of the esc,” European Heart Journal, vol. 33, no. 14, pp. 1787–1847, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. R. M. Lang, M. Bierig, R. B. Devereux et al., “Recommendations for chamber quantification: a report from the American Society of Echocardiography's guidelines and standards committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology,” Journal of the American Society of Echocardiography, vol. 18, no. 12, pp. 1440–1463, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. L. T. Cooper, K. L. Baughman, A. M. Feldman et al., “The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology,” Circulation, vol. 116, no. 19, pp. 2216–2233, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. K. L. Baughman, “Diagnosis of myocarditis: death of Dallas criteria,” Circulation, vol. 113, no. 4, pp. 593–595, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. H. T. Aretz, M. E. Billingham, W. D. Edwards et al., “Myocarditis: a histopathologic definition and classification,” The American Journal of Cardiovascular Pathology, vol. 1, no. 1, pp. 3–14, 1987. View at Google Scholar · View at Scopus
  32. M. Noutsias, B. Seeberg, H.-P. Schultheiss, and U. Kühl, “Expression of cell adhesion molecules in dilated cardiomyopathy: Evidence for endothelial activation in inflammatory cardiomyopathy,” Circulation, vol. 99, no. 16, pp. 2124–2131, 1999. View at Publisher · View at Google Scholar · View at Scopus
  33. A. L. P. Caforio, S. Pankuweit, E. Arbustini et al., “Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases,” European Heart Journal, vol. 34, no. 33, pp. 2636–2648, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. C. Rapezzi, E. Arbustini, A. L. P. Caforio et al., “Diagnostic work-up in cardiomyopathies: Bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases,” European Heart Journal, vol. 34, no. 19, pp. 1448–1458, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Huang, Y. Lin, S. Zhang et al., “Circulating Omentin-1 Levels Are Decreased in Dilated Cardiomyopathy Patients with Overt Heart Failure,” Disease Markers, vol. 2016, Article ID 6762825, 2016. View at Publisher · View at Google Scholar · View at Scopus
  36. T. Szabó, N. Scherbakov, A. Sandek et al., “Plasma adiponectin in heart failure with and without cachexia: Catabolic signal linking catabolism, symptomatic status, and prognosis,” Nutrition, Metabolism & Cardiovascular Diseases, vol. 24, no. 1, pp. 50–56, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Biolo, R. Shibata, N. Ouchi et al., “Determinants of Adiponectin Levels in Patients With Chronic Systolic Heart Failure,” American Journal of Cardiology, vol. 105, no. 8, pp. 1147–1152, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. J. S. Park, M. H. Cho, J. S. Nam et al., “Adiponectin is independently associated with apolipoprotein B to A-1 ratio in Koreans,” Metabolism - Clinical and Experimental, vol. 59, no. 5, pp. 677–682, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Springer, S. D. Anker, and W. Doehner, “Adiponectin resistance in heart failure and the emerging pattern of metabolic failure in chronic heart failure,” Circulation: Heart Failure, vol. 3, no. 2, pp. 181-182, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. H. Takano, J.-E. Obata, Y. Kodama et al., “Adiponectin is released from the heart in patients with heart failure,” International Journal of Cardiology, vol. 132, no. 2, pp. 221–226, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. A. M. Van Berendoncks, P. Beckers, V. Y. Hoymans et al., “β-blockers modify the prognostic value of adiponectin in chronic heart failure,” International Journal of Cardiology, vol. 150, no. 3, pp. 296–300, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. T. Isobe, S. Saitoh, S. Takagi et al., “Influence of gender, age and renal function on plasma adiponectin level: the Tanno and Sobetsu study,” European Journal of Endocrinology, vol. 153, no. 1, pp. 91–98, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. A. M. Van Berendoncks, A. Garnier, P. Beckers et al., “Exercise training reverses adiponectin resistance in skeletal muscle of patients with chronic heart failure,” Heart, vol. 97, no. 17, pp. 1403–1409, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Yamaji, T. Tsutamoto, T. Tanaka et al., “Effect of carvedilol on plasma adiponectin concentration in patients with chronic heart failure,” Circulation Journal, vol. 73, no. 6, pp. 1067–1073, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. E. Haugen, Y. Furukawa, A. Isic, and M. Fu, “Increased adiponectin level in parallel with increased NT-pro BNP in patients with severe heart failure in the elderly: A hospital cohort study,” International Journal of Cardiology, vol. 125, no. 2, pp. 216–219, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. R. S. Khan, T. S. Kato, A. Chokshi et al., “Adipose Tissue Inflammation and Adiponectin Resistance in Patients With Advanced Heart Failure: Correction After Ventricular Assist Device Implantation,” Circulation: Heart Failure, vol. 5, no. 3, pp. 340–348, 2012. View at Publisher · View at Google Scholar
  47. O. Tsukamoto, M. Fujita, M. Kato et al., “Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure,” Journal of the American College of Cardiology, vol. 53, no. 22, pp. 2070–2077, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. S. G. Wannamethee, P. Welsh, P. H. Whincup et al., “High adiponectin and increased risk of cardiovascular disease and mortality in asymptomatic older men: Does NT-proBNP help to explain this association?” European Journal of Preventive Cardiology, vol. 18, no. 1, pp. 65–71, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Masson, F. Gori, R. Latini et al., “Adiponectin in chronic heart failure: Influence of diabetes and genetic variants,” European Journal of Clinical Investigation, vol. 41, no. 12, pp. 1330–1338, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. F. Sam and K. Walsh, “What can adiponectin say about left ventricular function?” Heart, vol. 96, no. 5, pp. 331-332, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. J. R. Kizer, D. Benkeser, A. M. Arnold et al., “Associations of total and high-molecular-weight adiponectin with all-cause and cardiovascular mortality in older persons: The cardiovascular health study,” Circulation, vol. 126, no. 25, pp. 2951–2961, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. R. Jasaityte, M. Dandel, H. Lehmkuhl, and R. Hetzer, “rediction of short-term outcomes in patients with idiopathic dilated cardiomyopathy referred for transplantation using standard echocardiography and strain imaging,” Transplantation Proceedings, vol. 41, no. 1, pp. 277–280, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. J. Bogomolovas, K. Brohm, J. Čelutkiene et al., “Induction of Ankrd1 in dilated cardiomyopathy correlates with the heart failure progression,” BioMed Research International, vol. 2015, Article ID 273936, 2015. View at Publisher · View at Google Scholar · View at Scopus